title: 54-week results on infliximab attract attention at EULAR. European League against Rheumatism.
authors.forename: D
authors.initials: D
authors.lastname: Jack
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000628:therapy*; D006801:Humans; D000069285:Infliximab
chemical_list: D000911:Antibodies, Monoclonal; D000069285:Infliximab